BMRN Share Price

Open 82.29 Change Price %
High 83.39 1 Day -0.73 -0.89
Low 80.30 1 Week -1.26 -1.53
Close 81.02 1 Month -15.01 -15.63
Volume 1292675 1 Year -32.67 -28.74
52 Week High 118.48
52 Week Low 62.12
BMRN Important Levels
Resistance 2 83.88
Resistance 1 82.70
Pivot 81.57
Support 1 79.34
Support 2 78.16
NASDAQ USA Most Active Stocks
SIRI 4.11 -3.07%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
GRPN 4.10 -22.05%
NXPI 99.08 0.43%
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
RITT 0.06 50.00%
ZAZA 0.06 50.00%
LTBR 1.62 35.00%
SCHS 0.12 33.33%
ALTI 0.13 30.00%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
NASDAQ USA Top Losers Stocks
CACH 0.00 -100.00%
PTIX 0.00 -100.00%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
QTWW 0.08 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)

BMRN Technical Analysis 4
As on 27th Oct 2016 BMRN Share Price closed @ 81.02 and we RECOMMEND Sell for LONG-TERM with Stoploss of 88.42 & Strong Sell for SHORT-TERM with Stoploss of 92.64 we also expect STOCK to react on Following IMPORTANT LEVELS.
BMRN Target for October
1st Target up-side 98.01
2nd Target up-side 101.85
3rd Target up-side 105.7
1st Target down-side 87.03
2nd Target down-side 83.19
3rd Target down-side 79.34
BMRN Other Details
Segment EQ
Market Capital 6022899712.00
Sector Healthcare
Industry Biotechnology
Offical website
BMRN Address
770 Lindaro Street
San Rafael, CA 94901
United States
Phone: 415-506-6700
Fax: 415-382-7889
BMRN Latest News
Interactive Technical Analysis Chart BioMarin Pharmaceutical Inc. ( BMRN NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from
Your Comments and Response on BioMarin Pharmaceutical Inc.
BMRN Business Profile
BioMarin Pharmaceutical Inc. (BioMarin), incorporated in October 25, 1996, develops and commercializes pharmaceuticals for serious diseases and medical conditions. The Company’s product portfolio is comprised of four approved products and multiple investigational product candidates. Approved products include Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). It is conducting clinical trials on several product candidates for the treatment of various diseases. They include Vimizim (formerly referred to as GALNS), an enzyme replacement therapy for the treatment of Mucopolysaccharidosis Type IV or Morquio Syndrome Type A (MPS IV A), PEG-PAL, an enzyme substitution therapy for the treatment of phenylketonuria (PKU), BMN-701, an enzyme replacement therapy for Pompe disease, a glycogen storage disorder, BMN-673, an orally available poly (ADP-ribose) polymerase, or PARP inhibitor for the treatment of patients with certain cancers and BMN-111, a peptide therapeutic for the treatment of achondroplasia. On January 7, 2013, the Company acquired Zacharon Pharmaceuticals. The Company is conducting or planning to conduct preclinical development of several other enzyme product candidates for genetic and other metabolic diseases, including BMN-190 for the treatment of late infantile neuronal ceroid lipofuscinosis (LINCL), a form of Batten disease. The Company is developing Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder. PEG-PAL is an investigational enzyme substitution therapy that it is developing as a subcutaneous injection for the treatment of PKU. In preclinical models, PEG-PAL produced a rapid, dose-dependent reduction in blood phenylalanine (Phe) levels. BMN-673 is a PARP inhibitor, which is a class of molecules that has shown clinical activity against cancers involving defects in deoxyribonucleic acid (DNA) repair that it is investigating for the treatment of certain cancers. BMN-701 is a fusion of insulin-like growth factor 2 and alpha glucosidase (IGF2-GAA) in development for Pompe disease. Pompe disease is a lysosomal storage disorder caused by a deficiency in GAA, which prevents cells from adequately degrading glycogen. BMN-111 is a peptide therapeutic in development for the treatment of achondroplasia. The Company manufactures Naglazyme, Aldurazyme, Vimizim, PEG-PAL and BMN-111 in its production facilities located in Novato, California. Vialing and packaging are performed by contract manufacturers. Kuvan is manufactured on a contract basis by a third-party. Its Naglazyme, Kuvan and Firdapse customers include a limited number of specialty pharmacies and end-users, such as hospitals and foreign government agencies, which act as retailers. The Company also sells Naglazyme to its authorized European distributors and to certain pharmaceutical wholesalers.